Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor approved by the FDA across a broad range of cancers, including melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, MSI-H/dMMR colorectal cancer, hepatocellular carcinoma, and esophageal and gastric cancers, either as monotherapy or in combination with other therapies depending on the specific indication.
Opdivo blocks the PD-1 receptor on T cells, preventing cancer cells from using the PD-1/PD-L1 pathway to evade immune detection. By blocking this interaction, Opdivo helps restore the immune system's ability to recognize and attack cancer cells.
Opdivo is used across multiple cancer types and treatment settings — including advanced/metastatic disease, adjuvant therapy after surgery, and neoadjuvant therapy before surgery — with specific eligibility criteria varying by tumor type. A treating oncologist determines eligibility based on the exact cancer diagnosis and stage.
Dosing varies significantly by indication. A common regimen for melanoma monotherapy is 240 mg administered intravenously every 2 weeks, or 480 mg every 4 weeks, continued until disease progression or unacceptable toxicity, as determined by the treating oncologist.
Opdivo does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Opdivo can cause severe or fatal immune-mediated adverse reactions affecting any organ system, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and skin reactions. Patients should be monitored closely and managed with corticosteroids or treatment interruption as needed.
Fatal and other serious complications can occur in patients who undergo allogeneic hematopoietic stem cell transplantation before or after Opdivo treatment.
Infusion-related reactions have been reported. Treatment should be interrupted, slowed, or discontinued based on the severity of the reaction.
Opdivo may cause fetal harm. Effective contraception should be used during treatment and for a period after the final dose, as advised by the treating physician.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Opdivo is manufactured and marketed by Bristol-Myers Squibb. It is sourced through authorized distribution channels for patients seeking named-patient import into India. Opdivo is also approved in combination with relatlimab as Opdualag for certain melanoma patients.
Patients typically need a valid prescription from a treating oncologist confirming cancer diagnosis, stage, and relevant biomarker testing where applicable. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved immunotherapy across multiple cancer types, Opdivo is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Opdivo directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Opdivo requires refrigerated storage at 2°C to 8°C, protected from light, and must not be frozen or shaken. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Opdivo through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support oncology care coordination and documentation for Opdivo access.
Delhi's major hospitals assist patients with prescription support and documentation for Opdivo.
Bangalore's specialist network offers access coordination for eligible cancer patients seeking Opdivo.
Chennai-based oncology specialists coordinate Opdivo access alongside comprehensive immunotherapy care.
Hyderabad's care institutions support patients pursuing Opdivo therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Opdivo.
Pune-based specialists assist with prescription support and Opdivo treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Opdivo.
Kochi's specialist units assist patients with the documentation needed for Opdivo access.
Chandigarh's care centers support Opdivo treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Opdivo access process.
Lucknow-based centers assist patients pursuing Opdivo therapy.
Bhubaneswar's institutions support access to Opdivo for eligible patients.
Guwahati's specialists help coordinate Opdivo access for patients across the Northeast.
Patients in other cities across India can also access Opdivo through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
